Lucence

Thankful to be collaborating with Mayo! Learn more about LiquidHALLMARK at www.lucence.com

We're incredibly grateful to Deputy Prime Minister Gan Kim Yong for the highlight and visit to our Singapore laboratory! A real honor to share how our liquid biopsy technology allows patients to live longer and better.

Cancer is a global challenge, with close to 1 million deaths reported in India annually. We’re glad to announce a collaboration with Agilus Diagnostics to contribute to India's cancer care. For the first time, Indian cancer patients and physicians can now access LiquidHALLMARK® ctDNA and ctRNA to better personalize cancer treatment. LiquidHALLMARK® is the only such #liquidbiopsy test fully covered by US Medicare. Together, we can do better! Learn more: https://lnkd.in/d-YwBp5C

We are honored to collaborate with Mayo Clinic Laboratories to expand access to advanced cancer diagnostics. Together, we're delivering actionable genomic insights to support precision medicine and drive better outcomes worldwide! Learn more: https://lnkd.in/gPDZeNVQ #ctDNAandRNA #NoPatientLeftBehind

We're glad to share today that the LiquidHallmark ctDNA/ctRNA liquid biopsy test has been granted Medicare coverage through a decision by the Molecular Diagnostic Service (MolDx) program. This coverage decision means more cancer patients can access ctDNA/ctRNA testing, to identify more biomarkers for FDA-approved treatment options. So much thanks to the support of our physicians, patients and partners that enabled us to achieve this milestone for US and international cancer patients! Enterprise Singapore, SGInnovate, A*STAR - Agency for Science, Technology and Research.

Join Lucence at ESMO Asia 2024 in Singapore to learn more about multi-cancer screening! Our CEO, Min-Han Tan will be speaking at a session on how technology enables Multi-Cancer Early Detection (MCED) liquid biopsies. When: Saturday, 7 December 2024, 2:30 PM – 4:00 PM Where: Suntec City, Room 324 Do join us to hear how MCED is shaping the future of healthcare!

Big thanks to SGInnovate for this great video about what we do at Lucence -making cancer detection better and faster. Together we're making a difference! 💪✨

We’re thrilled to share that Lucence presented at the UBS Disruptive Technology CEO Summit 2024 in Hong Kong today! Our CEO, Min-Han Tan spoke on "Transforming Health: Multi-Cancer Screening in Blood", highlighting our mission to advance early cancer detection with LucenceINSIGHT™ for 50 cancers. This summit brings together innovators, and at Lucence, we’re proud to contribute with our liquid biopsy technology for earlier, more accurate cancer detection. A big thank you to UBS for this platform and to our Hong Kong partners, Gleneagles Hospital Hong Kong and Humansa, for your incredible support. Together, we’re building a future where earlier cancer detection saves more lives. 

We're grateful to receive NHIC’s Rising Star Healthcare Innovation Tribute! This recognition is made possible by our strong Public-Private Partnerships (PPPs) with National Cancer Centre Singapore, National University Hospital, Singapore General Hospital, Tan Tock Seng Hospital, and DxD Hub - Diagnostics Development Hub. Your support inspires us to keep working hard to improve healthcare for everyone. Congratulations to Biobot Surgical, Doctor Anywhere, and Mirxes on their outstanding achievements, and a big thank you to National Health Innovation Centre (NHIC) for a decade of fostering innovation and making meaningful change in healthcare. Here’s to many more years of collaboration and making a difference together! 🎉

"At Mr Eddie Low’s routine medical check-up in 2017, the doctor found something suspicious in his liver and one of his lungs. Further tests showed he had liver cancer and lung cancer. They were both primary cancers, meaning cancer did not spread from one organ to the other. A year later, Mr Low found out he had primary cancer in his prostate. Before Mr Low found out about his three primary cancers, he had no symptoms. “I didn’t feel like something was wrong. If I didn’t go for a medical screening, I would have probably found out much later." Most lung cancer cases, Dr. Patricia Kho (medical director of Icon Cancer Centre - Singapore at Mount Alvernia Hospital) says, are still being diagnosed at an advanced stage. About 61.5 per cent of men and 60.9 per cent of women who were diagnosed between 2018 and 2021 discovered their condition only at stage four. When lung cancer is detected early – such as in stage one, when the cancer has not spread – treatment can be effective. The five-year survival rate for stage one lung cancer patients can be as high as 92 per cent. But the five-year survival rate for stage four lung cancer patients is significantly lower at 10 per cent, she says." https://lnkd.in/gNJv8Gwm